Sort   by:  
 Page size 
UnknownPhase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Not available
S-EPMC4881377 | biostudies-literature
UnknownAdo-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Not available
S-EPMC6366814 | biostudies-literature
UnknownResponse to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Not available
S-EPMC8127357 | biostudies-literature
UnknownEfficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Not available
S-EPMC10373730 | biostudies-literature
UnknownAntitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Not available
S-EPMC5477238 | biostudies-literature
UnknownMolecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
Not available
S-EPMC10249779 | biostudies-literature
UnknownCeritinib in ALK-rearranged non-small-cell lung cancer.
Not available
S-EPMC4079055 | biostudies-literature
UnknownThe Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
Not available
S-EPMC7641983 | biostudies-literature
UnknownResponse to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.
Not available
S-EPMC5984717 | biostudies-literature
UnknownAn approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
Not available
S-EPMC5696266 | biostudies-literature
Sort   by:  
 Page size